A top 10 pharma company partnered with IQVIA to boost adoption of its lupus therapy, traditionally used in later lines of care. IQVIA developed an AI/ML-driven predictive field alerts program that identified patients likely to switch or initiate therapy after maintenance and steroid use, linking them to their treating HCPs. Monthly refreshed target lists enabled timely engagement. Over a year, the program drove 21,000 incremental prescriptions, delivering a 36% lift in new prescriptions and $10M in added revenue. The initiative achieved 720% ROI, with rheumatologists and mid-priority HCPs showing the strongest gains.

Join for free to read